{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:45:40Z","timestamp":1793375140431,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":1462,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.kint.2016.04.008","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T01:05:58Z","timestamp":1465261558000},"page":"638-647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":622,"title":["Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"90","author":[{"given":"Frank B.","family":"Cortazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan L.","family":"Troxell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Ralto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie P.","family":"Hoenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J.","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya G.","family":"Glezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn D.","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michifumi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2016.04.008_bib1","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2016.04.008_bib2","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.kint.2016.04.008_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1615\/CritRevImmunol.v24.i4.10","article-title":"Negative regulation of T-cell function by PD-1","volume":"24","author":"Zha","year":"2004","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.kint.2016.04.008_bib4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2016.04.008_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.04.008_bib6","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.04.008_bib7","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2016.04.008_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.04.008_bib9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.04.008_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.04.008_bib11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.kint.2016.04.008_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.04.008_bib13","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","article-title":"Ipilimumab granulomatous interstitial nephritis","volume":"22","author":"Thajudeen","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.kint.2016.04.008_bib14","first-page":"4607","article-title":"Ipilimumab-induced immune-related renal failure\u2014a case report","volume":"32","author":"Forde","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.kint.2016.04.008_bib15","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2016.04.008_bib16","unstructured":"Mae H, Timbol MD, Shirali AC. Acute interstitial nephritis from anti-PD1 therapy with pembrolizumab in two patients with advanced non-small cell lung cancer. [TH-P01051] Abstract presented at: Kidney Week, American Society of Nephrology, November 5, 2015; San Diego, CA."},{"key":"10.1016\/j.kint.2016.04.008_bib17","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1093\/ndt\/gfh485","article-title":"Acute interstitial nephritis: clinical features and response to corticosteroid therapy","volume":"19","author":"Clarkson","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.04.008_bib18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/sj.ki.5002776","article-title":"Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis","volume":"73","author":"Gonzalez","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.04.008_bib19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2014.04.027","article-title":"Biopsy-proven acute interstitial nephritis, 1993\u20132011: a case series","volume":"64","author":"Muriithi","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.04.008_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.kint.2016.04.008_bib21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.kint.2016.04.008_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"94","key":"10.1016\/j.kint.2016.04.008_bib23","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1111\/j.1523-1755.2005.09423.x","article-title":"The role of tubulointerstitial inflammation","author":"Zheng","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2016.04.008_bib24","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1681\/ASN.2006050418","article-title":"Involvement of drug-specific T cells in acute drug-induced interstitial nephritis","volume":"17","author":"Spanou","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.04.008_bib25","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.00980209","article-title":"Renal involvement in primary Sjogren's syndrome: a clinicopathologic study","volume":"4","author":"Maripuri","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.04.008_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.kint.2016.04.008_bib27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-15-0193","article-title":"Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab","volume":"4","author":"Weber","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.kint.2016.04.008_bib28","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2016.04.008_bib29","first-page":"908","article-title":"Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia","volume":"25","author":"George","year":"2011","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.kint.2016.04.008_bib30","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2016.04.008_bib31","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.2215\/CJN.12651214","article-title":"Kinetic eGFR and novel AKI biomarkers to predict renal recovery","volume":"10","author":"Dewitte","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.04.008_bib32","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), version 4.0","year":"2009"},{"key":"10.1016\/j.kint.2016.04.008_bib33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816301648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816301648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T22:22:11Z","timestamp":1598998931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253816301648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0085253816301648"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2016.04.008","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2016.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}